DXRHealthcare · Medical Instruments & Supplies

DXR Stock Forecast: Daxor Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$10

−2.91% on the day

The 2 Wall Street analysts covering Daxor Corp. hold a median 12-month price target of $23 — +125.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap

$58.4M

Ticker Nerd rank

80 / 100

Median analyst target

$23

Analysts covering

Total return, dividends reinvested

−3.8%

−4.9%

YTD

−32.2%

−7.7%

From 52W high

−32.2%

From 52W low

+12.7%

$15

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

DXR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Daxor Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth

Volatility

Size

Value

Issuance

Momentum

Revisions

Quality

Accruals

Growth (99): Sales and profits are climbing, and climbing faster than before.

Accruals (12): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DXR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DXR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $22Median $23High $23

The green dot is the last close — the median target sits +125.0% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
17 Mar 2025	Ascendiant Capital	Maintains	Buy	$25 → $25
9 Sept 2024	Ascendiant Capital	Maintains	Buy	—
25 Mar 2021	Ascendiant Capital	Assumes	Buy	$21
29 July 2019	Maxim Group	Initiates	Buy	—
16 May 2019	Ascendiant	Initiates	Buy	—
16 May 2019	Ascendiant Capital	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DXR appears on the weeks it earns a place.

Performance

DXR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Aug 2026, Daxor Corp. returned −7.7% against +21.8% for the S&P 500, dividends included.

DXR vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DXR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Daxor Corp. (DXR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 6.1×
Price / sales: 2187.6×
Price / book: 1.1×
EV / EBITDA: —

Growth & margins

Revenue growth (YoY): −82.6%
Earnings growth (YoY): 340.2%
Gross margin: —
Operating margin: −9660.6%
Net margin: 34359.2%

Returns & dividend

Return on equity: 22.5%
Return on assets: −1.6%
Dividend yield: 0.6%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Daxor Corp. (DXR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Daxor Corp. has a market value of $58.4M and an enterprise value of $0.0.
Shares outstanding: 5.1M.
Trailing P/E: 6.1×; forward P/E: −333.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.60%, paying out 0% of earnings.
Daxor Corp. employs 0 people.

market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

DXR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies

Company	Market cap	TKN rank
DXRDaxor Corp.	$58.4M	80
POCIPrecision Optics Corp., Inc.	$49.8M	58
NEPHNephros, Inc.	$43.4M	91
MLSSMilestone Scientific, Inc.	$42.3M	85
HBIOHarvard Bioscience, Inc.	$33.5M	98
FEMYFemasys, Inc.	$24.8M	50
ZJYLJin Medical International Ltd.	$23.8M	22

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Daxor Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DXR news & analysis

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

GlobeNewsWire · 30 July 2026positive

Daxor Corporation announced the launch of a new outpatient Blood Volume Analysis (BVA) program at a healthcare facility in eastern Kansas, expanding its presence in Midwestern outpatient care through its CLIA-certified send-out model.

Why it matters — The expansion into a new Midwestern outpatient facility signals continued commercial momentum for Daxor's blood volume diagnostic services beyond its existing footprint.

FAQ

Frequently asked questions about DXR stock

What is the DXR stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Daxor Corp. have a median 12-month price target of $23, with estimates ranging from $22 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DXR stock a buy right now?

Of the 2 analysts covering Daxor Corp., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Daxor Corp. 80 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DXR?

As at 22 Aug 2026, Daxor Corp. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will DXR stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +125.0% from the last close, and Ticker Nerd's factor model ranks Daxor Corp. 80 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DXR stock forecast for 2030?

No analyst covering Daxor Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DXR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $23 over the next 12 months.

How has DXR stock performed over the past year?

Daxor Corp. returned -7.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Daxor Corp. do?

What is the latest news on DXR?

The most recent item we track (GlobeNewsWire, 30 July 2026): "Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas". Daxor Corporation announced the launch of a new outpatient Blood Volume Analysis (BVA) program at a healthcare facility in eastern Kansas, expanding its presence in Midwestern outpatient care through its CLIA-certified send-out model.

Company

About Daxor Corp.

Daxor Corporation is a medical instrumentation and biotechnology company focused on providing innovative solutions for blood volume analysis. Its primary product, the Blood Volume Analyzer (BVA-100), is a diagnostic tool used to precisely quantify the blood volume status of patients. This capability assists healthcare professionals in making informed decisions regarding fluid management, which is critical in treating conditions such as heart failure, hypertension, and trauma. Daxor's technology plays a vital role in enhancing patient outcomes and optimizing treatment in both surgical and intensive care settings. The company's contributions are significant in the healthcare sector, where accurate patient monitoring can have life-saving implications. Headquartered in New York, Daxor also actively engages in ongoing research and development to expand the applications of its patented technology, aiming to address unmet needs in patient care. Within the financial market, Daxor represents a niche player in the biomedical devices and diagnostics industry, drawing interest from investors who focus on innovative healthcare technologies. Its role in enhancing diagnostic accuracy underscores its importance in the medical field."}

CEO Mr. Michael Richard Feldschuh · United States · https://www.daxor.com